Injectable Phage-Loaded Microparticles Effectively Release Phages to Kill Methicillin-Resistant Staphylococcus aureus

Yajing Xu, Tao Yang, Yao Miao, Qinglei Zhang, Mingying Yang, Chuanbin MaoACS 2024 · DOI

TL;DR

This paper presents a novel approach to combat antibiotic-resistant bacteria like MRSA by developing injectable microparticles loaded with bacteriophages. These "Phage-MPs," made from silk fibroin and modified with polyethylenimine, effectively deliver phages to infection sites, release them in a controlled manner, and demonstrate potent antibacterial activity both in vitro and in vivo, offering a promising alternative to conventional antibiotics.

What Problem Does This Paper Address?

The escalating crisis of multidrug-resistant bacteria, particularly Methicillin-Resistant Staphylococcus aureus (MRSA), poses a significant threat to global public health. While bacteriophages (viruses that infect and kill bacteria) show immense promise as an alternative to antibiotics, their clinical application is hampered by challenges in efficient delivery and controlled release to infection sites. Free phages can be rapidly cleared from the body and may not reach therapeutic concentrations locally. This research addresses the need for an effective delivery system that can protect phages, deliver them to the target site, and ensure sustained release for optimal therapeutic outcomes.

Methods

The core innovation lies in the development of Phage-Loaded Microparticles (Phage-MPs). The process involves:

  • Silk Fibroin Microparticle (SF-MP) Synthesis: Porous SF-MPs were created using a microemulsion and freezing phase separation method, leveraging the biocompatibility and biodegradability of silk fibroin.
  • Surface Modification: SF-MPs were coated with positively charged polyethylenimine (PEI) to create PEI-MPs. This modification was crucial for the next step.
  • Phage Loading: Lytic bacteriophages specific to S. aureus were electrostatically attached to the PEI-modified SF-MPs. The positive charge of PEI facilitated strong binding with the negatively charged phages.
  • Characterization: Various techniques were employed, including Scanning Electron Microscopy (SEM) and Transmission Electron Microscopy (TEM) to visualize the microparticles and phages, zeta potential measurements to confirm surface charge modifications, and fluorescent labeling to verify phage attachment.
  • Phage Release Kinetics: The controlled release of phages from the Phage-MPs was studied over time.
  • In Vitro Antibacterial Activity: The efficacy of Phage-MPs against S. aureus and MRSA was assessed using plate-count assays and SEM to observe bacterial morphology changes. Live/Dead staining was also used to differentiate between live and dead bacteria.
  • Biocompatibility Assays: Hemolytic activity and cytotoxicity tests (using CCK-8 assay on human epithelial cells) were performed to evaluate the safety of the Phage-MPs.
  • In Vivo Antibacterial Study: A mouse model of abdominal MRSA infection was used to evaluate the therapeutic efficacy of Phage-MPs. This involved monitoring body weight changes, survival rates, and quantifying bacterial loads in major organs. Histopathological analysis (H&E staining) of organs was also conducted.

Datasets

Not discussed in the paper. The study utilized bacterial strains (S. aureus 9118 and MRSA N315) and human epithelial cells (293T) for in vitro experiments, and male BALB/c mice for in vivo studies.

Key Insights and Ideas

  • Electrostatic Adsorption as a Key Mechanism: The use of PEI to create a positively charged surface on SF-MPs was critical for efficiently and stably loading negatively charged phages. This simple yet effective electrostatic interaction is a cornerstone of the Phage-MP design.
  • Controlled Phage Release is Crucial: The Phage-MPs demonstrated a desirable release profile: an initial burst followed by sustained release. This is hypothesized to be ideal for rapidly clearing initial bacterial loads and then maintaining therapeutic concentrations to prevent recurrence.
  • Phage-MPs Outperform Free Phages in Vivo: While free phages showed some antibacterial activity, the Phage-MPs significantly improved therapeutic outcomes in the mouse model, reducing bacterial load in organs and increasing survival rates. This highlights the advantage of a controlled delivery system.
  • Excellent Biocompatibility: The Phage-MPs exhibited minimal toxicity to mammalian cells and red blood cells, and histopathological analysis of organs in the in vivo study showed no significant adverse effects, underscoring their safety profile.
  • Potential for Broad Applicability: The authors suggest that the electrostatic adsorption method is versatile and can be used to load multiple phages, paving the way for phage cocktail therapies against complex, multi-strain infections.

Key Results

  • High Phage Loading Capacity: SF-MPs, with their high surface area, could load phages to a concentration of approximately 1.25 × 10<sup>10</sup> plaque-forming units (pfu) per mg of microparticles.
  • Potent In Vitro Antibacterial Activity: Phage-MPs achieved bactericidal efficiencies of 99.7% for S. aureus and 98.1% for MRSA at a concentration of 25 µg/mL, reaching 99.9% at 400 µg/mL.
  • Improved In Vivo Efficacy: In the abdominal MRSA infection model, Phage-MP treatment led to a significant reduction in bacterial load in major organs and improved survival rates compared to PBS or SF-MPs alone.
  • Comparable to Vancomycin: The in vivo antibacterial efficacy of Phage-MPs was comparable to vancomycin, a standard antibiotic, and even showed advantages in terms of faster recovery and controlled inflammation.
  • Negligible Cytotoxicity and Hemolysis: Cell viability assays showed no significant difference between cells treated with Phage-MPs and the control group. Hemolysis rates were also within acceptable limits.

Limitations and Future Work

  • Single Strain Focus: The current study focused on S. aureus and MRSA. The authors acknowledge that clinical infections often involve complex, multi-strain mixtures.
  • Phage Cocktail Therapy: While the method is adaptable for phage cocktails, further research is needed to optimize the loading and release of multiple phage types simultaneously.
  • In Vivo Biodistribution: While the study demonstrated reduced bacterial load in organs, a detailed analysis of the biodistribution and clearance of the Phage-MPs themselves in vivo was not extensively detailed.
  • Long-Term Efficacy and Resistance: While the paper highlights the potential to overcome antibiotic resistance, long-term studies on the emergence of phage resistance and the sustained therapeutic effects would be valuable.

The authors suggest that this work lays the foundation for a new generation of phage-based therapies, particularly for combating antibiotic-resistant bacterial infections, and the versatility of the Phage-MP platform opens avenues for addressing diverse infectious diseases.

Summary updated

Abstract

The increasing prevalence of bacterial multidrug antibiotic resistance has led to a serious threat to public health, emphasizing the urgent need for alternative antibacterial therapeutics. Lytic phages, a class of viruses that selectively infect and kill bacteria, offer promising potential as alternatives to antibiotics. However, injectable carriers with a desired release profile remain to be developed to deliver them to infection sites. To address this challenge, phage-loaded microparticles (Phage-MPs) have been developed to deliver phages to the infection site and release phages for an optimal therapeutic effect. The Phage-MPs are synthesized by allowing phages to be electrostatically attached onto the porous polyethylenimine-modified silk fibroin microparticles (SF-MPs). The high specific surface area of SF-MPs allows them to efficiently load phages, reaching about 1.25 × 10<sup>10</sup> pfu per mg of microparticles. The Phage-MPs could release phages in a controlled manner to achieve potent antibacterial activity against methicillin-resistant <i>Staphylococcus aureus</i> (MRSA). Unlike the diffuse biodistribution of free phages post-intraperitoneal injection, Phage-MPs could continuously release phages to effectively boost the local phage concentration at the bacterial infection site after they are intraperitoneally injected into an abdominal MRSA-infected mouse model. In a mouse abdominal MRSA infection model, Phage-MPs significantly reduce the bacterial load in major organs, achieving an efficient therapeutic effect. Furthermore, Phage-MPs demonstrate outstanding biocompatibility both in vitro and in vivo. Overall, our research lays the foundation for a new generation of phage-based therapies to combat antibiotic-resistant bacterial infections.
BibTeX
@inproceedings{xu2024injectable,
  author = {Yajing Xu and Tao Yang and Yao Miao and Qinglei Zhang and Mingying Yang and Chuanbin Mao},
  title = {{Injectable Phage-Loaded Microparticles Effectively Release Phages to Kill Methicillin-Resistant <i>Staphylococcus aureus</i>}},
  booktitle = {ACS},
  year = {2024},
  doi = {10.1021/acsami.3c19443},
}
Figure